A phase II/III study of immunomodulation after high-dose myeloablative therapy with autologous stem cell rescue for refractory/relapsed Hodgkin disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Carmustine; Ciclosporin; Cytarabine; Etoposide; Filgrastim; Interferon gamma; Interleukin-2; Melphalan
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 Oct 2013 Biomarkers information updated
- 07 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2007 Status change from suspended to in progress.